{"url_path":"/sec/qnrx/8-k/2026-06-04/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1671502/0001104659-26-070501-index.html","accession_number":"0001104659-26-070501","cik":"0001671502","ticker":"QNRX","issuer_name":"Quoin Pharmaceuticals Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671502/0001104659-26-070501-index.html","primary_entity_key":"0001671502","primary_entity_name":"Quoin Pharmaceuticals, Ltd."},"word_count":354,"has_tables":true,"body_markdown":"false\n0001671502\n\n0001671502\n\n2026-06-04\n2026-06-04\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported):\n**June 4, 2026**\n\n \n\n**QUOIN\nPHARMACEUTICALS LTD.**\n\n(Translation of registrant’s name into English)\n\n \n\n**State of Israel**\n \n**001-37846**\n \n**92-2593104**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission File Number)\n \n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**42127 Pleasant Forest Court**\n\n**Ashburn, VA**\n\n \n**20148-7349**\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(703) 980-4182**\n\n \n\n**Not applicable**\n\n(Former name or former address, if changed since last report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see*General\nInstruction A.2. below):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered\npursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading\nSymbol(s)**\n \n**Name of each exchange on which registered**\n\nAmerican Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share\n \nQNRX\n \nThe Nasdaq Stock Market LLC\n\nOrdinary Shares, no par value per share*\n \n \n \nN/A\n\n \n\n*Not for trading, but only in connection with the registration of the American Depositary Shares pursuant\nto requirements of the Securities and Exchange Commission.\n\n \n\nIndicate by check\nmark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this\nchapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}